Join Growin Stock Community!

Atea pharmaceuticals, inc.AVIR.US Overview

US StockHealthcare
(No presentation for AVIR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AVIR AI Insights

AVIR Overall Performance

AVIR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AVIR Recent Performance

0.73%

Atea pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AVIR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AVIR Key Information

AVIR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AVIR Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Price of AVIR

AVIR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AVIR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.90
PB Ratio
1.16
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.90
PB Ratio
1.16
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is AVIR's latest earnings report released?

    The most recent financial report for Atea pharmaceuticals, inc. (AVIR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AVIR's short-term business performance and financial health. For the latest updates on AVIR's earnings releases, visit this page regularly.

  • How much debt does AVIR have?

    As of the end of the reporting period, Atea pharmaceuticals, inc. (AVIR) had total debt of 1.05M, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AVIR have?

    At the end of the period, Atea pharmaceuticals, inc. (AVIR) held Total Cash and Cash Equivalents of 77.34M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is AVIR's EPS continuing to grow?

    According to the past four quarterly reports, Atea pharmaceuticals, inc. (AVIR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AVIR?

    Atea pharmaceuticals, inc. (AVIR)'s Free Cash Flow (FCF) for the period is -40.38M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 75.28% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.